Novel sulfobutyl ether cyclodextrin gradient leads to highly active liposomal irinotecan formulation

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 6, 2011, Pages 765-773

  Li, Chunlei ^a,c   Cui, Jingxia ^b   Wang, Caixia ^a,c   Li, Yanhui ^a,c   Zhang, Lan ^a,c   Xiu, Xian ^a,c   Li, Yongfeng ^a,c   Wei, Na ^a,c   Zhang, Li ^a,c   Wang, Ping ^d  

^a CSPC ZhongQi Pharmaceutical Technology (Shijiazhuang) Co Ltd   (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

^c Hebei Pharmaceutical Engineering and Technology Research Center   (China)

^d Hebei Chemical Medicine Vocational Technology College   (China)

Author keywords

drug loading; irinotecan; liposomes; sulfobutyl ether cyclodextrin; therapeutic index

Indexed keywords

AMMONIA; BETA CYCLODEXTRIN SULFOBUTYL ETHER; IRINOTECAN; LIPOSOME; MACROGOL; TETRYLAMMONIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG RETENTION; DRUG STRUCTURE; FEMALE; IN VITRO STUDY; LIPOSOMAL DELIVERY; MALE; MOUSE; NANOENCAPSULATION; NONHUMAN; PROSTATE CANCER; TOXICITY TESTING;

AMMONIUM SULFATE; ANIMALS; ANTINEOPLASTIC AGENTS; BETA-CYCLODEXTRINS; CAMPTOTHECIN; CAPSULES; FEMALE; HALF-LIFE; LIPIDS; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; POLYETHYLENE GLYCOLS; PROSTATIC NEOPLASMS; TECHNOLOGY, PHARMACEUTICAL;

EID: 79956217709     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2011.01272.x     Document Type: Article

References (40)

1. Reardon DA, et al,. Irinotecan: promising activity in the treatment of malignant glioma. Oncology (Huntingt) 2003; 17 (Suppl. 5): 9-14.
2. Mathijssen RH, et al,. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr Cancer Drug Targets 2002; 2: 103-123. (Pubitemid 34625479)
3. Kelly K,. Current role of irinotecan in the treatment of non-small-cell lung cancer. Oncology (Huntingt) 2002; 16: 1153-1162, 1165; discussion 1165-1156 passim.
4. Weekes J, et al,. Irinotecan therapy and molecular targets in colorectal cancer: a systemic review. World J Gastroenterol 2009; 15: 3597-3602.
5. Farhat FS,. A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer. Med Oncol 2007; 24: 137-146. (Pubitemid 350139221)
6. Mitry E, et al,. Irinotecan as palliative chemotherapy for metastatic colorectal cancer: evolving tactics following initial treatment. Int J Colorectal Dis 2009; 24: 605-612.
7. Hebbar M, et al,. Current place of high-dose irinotecan chemotherapy in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol 2009; 135: 749-752.
8. Sastre J, et al,. Irinotecan in the treatment of elderly patients with advanced colorectal cancer. Crit Rev Oncol Hematol 2008; 68: 250-255.
9. Kawahara M,. Irinotecan in the treatment of small cell lung cancer: a review of patient safety considerations. Expert Opin Drug Saf 2006; 5: 303-312. (Pubitemid 43379627)
10. Maurer-Spurej E, et al,. Factors influencing uptake and retention of amino-containing drugs in large unilamellar vesicles exhibiting transmembrane pH gradients. Biochim Biophys Acta 1999; 1416: 1-10. (Pubitemid 29065419)
11. Cullis PR, et al,. pH gradients and membrane transport in liposomal systems. Trends Biotechnol 1991; 9: 268-272. (Pubitemid 121003120)
12. Tardi P, et al,. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res 2000; 60: 3389-3393. (Pubitemid 30482152)
13. Mayer LD, et al,. Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim Biophys Acta 1986; 857: 123-126. (Pubitemid 16085119)
14. Lasic DD, et al,. Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery. Biochim Biophys Acta 1995; 1239: 145-156.
15. Haran G, et al,. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1993; 1151: 201-215. (Pubitemid 23283973)
16. Lasic DD, et al,. Gelation of liposome interior. A novel method for drug encapsulation. FEBS Lett 1992; 312: 255-258.
17. Hattori Y, et al,. Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors. J Controlled Release 2009; 136: 30-37.
18. Ramsay EC, et al,. Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors. Clin Cancer Res 2008; 14: 1208-1217. (Pubitemid 351302570)
19. Ramsay E, et al,. A novel liposomal irinotecan formulation with significant anti-tumour activity: use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention. Eur J Pharm Biopharm 2008; 68: 607-617. (Pubitemid 351318211)
20. Dicko A, et al,. Intra and inter-molecular interactions dictate the aggregation state of irinotecan co-encapsulated with floxuridine inside liposomes. Pharm Res 2008; 25: 1702-1713.
21. Dickinson PJ, et al,. Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging: laboratory investigation. J Neurosurg 2008; 108: 989-998. (Pubitemid 351656848)
22. Baker JH, et al,. Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin. Clin Cancer Res 2008; 14: 7260-7271.
23. Tardi PG, et al,. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochim Biophys Acta 2007; 1768: 678-687. (Pubitemid 46275599)
24. Krauze MT, et al,. Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. Neuro-oncology 2007; 9: 393-403.
25. Dicko A, et al,. Role of copper gluconate/triethanolamine in irinotecan encapsulation inside the liposomes. Int J Pharm 2007; 337: 219-228. (Pubitemid 46756052)
26. Ramsay E, et al,. Transition metal-mediated liposomal encapsulation of irinotecan (CPT-11) stabilizes the drug in the therapeutically active lactone conformation. Pharm Res 2006; 23: 2799-2808. (Pubitemid 44885367)
27. Noble CO, et al,. Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res 2006; 66: 2801-2806.
28. Chou TH, et al,. Effect of composition on the stability of liposomal irinotecan prepared by a pH gradient method. J Biosci Bioeng 2003; 95: 405-408.
29. Sadzuka Y, et al,. Effective irinotecan (CPT-11)-containing liposomes: intraliposomal conversion to the active metabolite SN-38. Jpn J Cancer Res 1999; 90: 226-232. (Pubitemid 29112324)
30. Sadzuka Y, et al,. Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11. Cancer Lett 1998; 127: 99-106. (Pubitemid 28230791)
31. Drummond DC, et al,. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999; 51: 691-743.
32. Drummond DC, et al,. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res 2006; 66: 3271-3277.
33. Cui J, et al,. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy? J Control Release 2007; 118: 204-215. (Pubitemid 46350710)
34. Rocha Lima CM, Chiappori A,. Treatment of relapsed small-cell lung cancer-a focus on the evolving role of topotecan. Lung Cancer 2003; 40: 229-236. (Pubitemid 36627702)
35. Nabiev I, et al,. Spectroscopic and biochemical characterisation of self-aggregates formed by antitumor drugs of the camptothecin family: their possible role in the unique mode of drug action. Biochem Pharmacol 1998; 55: 1163-1174. (Pubitemid 28206704)
36. Fukuda M, et al,. Influence of sulfobutyl ether beta-cyclodextrin (Captisol) on the dissolution properties of a poorly soluble drug from extrudates prepared by hot-melt extrusion. Int J Pharm 2008; 350: 188-196.
37. Jarvinen T, et al,. Sulfobutyl ether beta-cyclodextrin (SBE-beta-CD) in eyedrops improves the tolerability of a topically applied pilocarpine prodrug in rabbits. J Ocul Pharmacol Ther 1995; 11: 95-106.
38. Fenske DB, Cullis PR,. Entrapment of small molecules and nucleic acid-based drugs in liposomes. Methods Enzymol 2005; 391: 7-40. (Pubitemid 40254027)
39. Fenske DB, et al,. Ionophore-mediated uptake of ciprofloxacin and vincristine into large unilamellar vesicles exhibiting transmembrane ion gradients. Biochim Biophys Acta 1998; 1414: 188-204. (Pubitemid 28511050)
40. Aiyama R, et al,. Determination of self-association of irinotecan hydrochloride (CPT-11) in aqueous solution. Chem Pharm Bull 1992; 55: 2810-2813.